A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

At the time, it said the decision was taken after a look at the market opportunity for biosimilar Lantus, particularly in light of the anticipated pricing for the product, as well as the cost of ...

while some pay a percentage of the medicine’s cost. The new cut-price rival will increase the pressure on both Sanofi and Novo Nordisk. Sales of Sanofi's Lantus are already sliding in Europe ...